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GABAA1 and GABAC receptors are both GABA-gated chloride channels but with very different pharmacological properties. In fact, that is the basis for their classification. Although
both types of receptors can be activated by GABA, the GABAA
receptor can be specifically antagonized by bicuculline. In contrast, the GABAC receptor is insensitive to bicuculline but can
be selectively antagonized by 1,2,5,6-tetrahydropyridine-4-yl)methylphosphinic acid (1). The functional properties of these
two types of GABA receptors are also different. For example,
* This research was supported by National Institutes of Health Grant
NS35291 (to D. S. W.) and Training Grant DK07545 (to Y. C.). The costs
of publication of this article were defrayed in part by the payment of
page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this
fact.
储 To whom correspondence should be addressed: Division of Neurobiology, Barrow Neurological Institute, 350 West Thomas Rd., Phoenix,
AZ 85013. Tel.: 602-406-6192; Fax: 602-406-4572; E-mail: yongchang.
chang@chw.edu.
1
The abbreviations used are: GABA, ␥-aminobutyric acid; GABAA,
GABA receptor, type A; GABAC, GABA receptor, type C; AChBP, acetylcholine-binding protein; 3-APA, 3-aminopropylphosphonic acid; MTSET, methanethiosulfonate ethyltrimethylammonium.
This paper is available on line at http://www.jbc.org

the GABAC receptor has higher GABA sensitivity but slower
activation and deactivation kinetics than the GABAA receptor
(2). The GABAC receptor also shows almost no desensitization
(2), whereas the GABAA receptor exhibits strong desensitization (3). Although the functional differences could arise from
differences in the structural architecture of the GABA binding
pockets, distinct antagonist profiles of GABAA and GABAC
receptors indicate that their agonist/antagonist binding pockets are not the same. Studies over the last 15 years have
shaped a relatively complete model for the GABAA receptor
(4 –9). In contrast, structural information on the GABAC receptor agonist binding pocket is far from complete. Some candidate
binding residues in several potential “binding loops” are still
undefined.
GABA-gated ion channels belong to the ligand-gated ion
channel family, which also includes nicotinic acetylcholine receptors, serotonin-3 receptors, and glycine receptors. The study
of nicotinic receptors in the past two decades has shaped a
structural model for the ligand-gated ion channel family. In
this model, six loops designated A–F have been identified to
participate in the formation of the agonist binding pocket (10).
This structural model was further confirmed and extended by
the crystal structure of the homologous acetylcholine-binding
protein, AChBP (11). Cumulating evidence suggests a similar
general structural architecture for all members of this ligandgated ion channel family. For example, in the GABA receptor,
two ligand binding domains identified in the ␤2 subunit (4) and
the 1 subunit (2) can be mapped to the homologous residues in
loops B and C. One binding domain identified in the ␣1 subunit
(5, 12) and also in the 1 subunit (13) can be mapped to loop D
in the complementary face. More recently, two residues contributed from loop A of the ␤2 subunit (7), three residues from
loop F (8), and two residues from loop E of the ␣1 subunit of the
GABAA receptor have been identified as binding residues (9).
Furthermore, the secondary structure of the GABA receptor is
in agreement with the AChBP-based structural model (6 – 8).
Due to agonist specificity and sequence diversity, key residues
involved in agonist binding in different ligand-gated ion channels are not the same. Nevertheless, the similarity of the general architecture in this receptor family suggests that the
AChBP-based structural model can be used as a guideline in
search of the complete model of the GABA receptor agonist
binding pocket.
The substituted cysteine accessibility method was first implemented in ion channels to identify pore-lining residues in
nicotinic and GABA receptors (14 –16). This approach is based
on a functional effect of modification of the substituted cysteine
by a water-soluble sulfhydryl-reactive compound. If such a
modification occurs in a functionally important domain of the
receptor, it is likely to produce a change in receptor function.
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␥-Aminobutyric acid (GABA) is the major inhibitory
neurotransmitter in the mammalian brain. The GABA
receptor type C (GABAC) is a ligand-gated ion channel
with pharmacological properties distinct from the
GABAA receptor. To date, only three binding domains in
the recombinant 1 GABAC receptor have been recognized among six potential regions. In this report, using
the substituted cysteine accessibility method, we
scanned three potential regions previously unexplored
in the 1 GABAC receptor, corresponding to the binding
loops A, E, and F in the structural model for ligand-gated
ion channels. The cysteine accessibility scanning and
agonist/antagonist protection tests have resulted in the
identification of residues in loops A and E, but not F,
involved in forming the GABAC receptor agonist binding
pocket. Three of these newly identified residues are in a
novel region corresponding to the extended stretch of
loop E. In addition, the cysteine accessibility pattern
suggests that part of loop A and part of loop E have a
␤-strand structure, whereas loop F is a random coil.
Finally, when all of the identified ligand binding residues are mapped onto a three-dimensional homology
model of the amino-terminal domain of the 1 GABAC
receptor, they are facing toward the putative binding
pocket. Combined with previous findings, a complete
model of the GABAC receptor binding pocket was proposed and discussed in comparison with the GABAA receptor binding pocket.
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EXPERIMENTAL PROCEDURES

Mutagenesis and cRNA Preparation—The cDNA encoding the human 1 GABA receptor subunit was cloned into the pGEMHE vector in
the T7 orientation (20). The residues in the amino-terminal segments
corresponding to loops A, E, and F in nicotinic receptor subunits were
mutated to cysteine, one at a time, using the PCR-based QuikChange
method of site-directed mutagenesis (Stratagene, Hercules, CA). The
mutations were confirmed by automated DNA sequencing. The fragments containing individual mutations were subcloned and resequenced to avoid additional mutations. The wild type and mutant
cDNAs were then linearized by NheI digestion. The cRNAs were transcribed by standard in vitro transcription protocols. Briefly, RNase-free
DNA templates were prepared by treating linearized DNA with proteinase K. cRNAs then were transcribed by T7 RNA polymerase. After
degradation of the DNA template by RNase-free DNase I, the cRNAs
were purified and resuspended in diethyl pyrocarbonate-treated water.
cRNA yield and integrity were examined on a 1% agarose gel.
Oocyte Preparation and Receptor Expression—Female Xenopus laevis
(Xenopus I, Ann Arbor, MI) were anesthetized by 0.2% MS-222. The
ovarian lobes were surgically removed from the frog and placed in
calcium-free oocyte Ringer (OR2) incubation solution consisting of (in
mM) 82.5 NaCl, 2.5 KCl, 1 MgCl2, 1 Na2HPO4, and 5 HEPES; 50
units/ml penicillin, and 50 g/ml streptomycin, pH 7.5. The frog was
then allowed to recover from surgery before being returned to the
incubation tank. The lobes were cut into small pieces and digested with
0.3% collagenase A (Roche Applied Science) with constant stirring at
room temperature for 1.5–2 h. The dispersed oocytes were thoroughly
rinsed with the above solution plus 1 mM CaCl2. The stage VI oocytes
were selected, and the follicular layer (if still present) was manually
removed with fine forceps. The oocytes were incubated at 16 °C before
injection.
Micropipettes for cRNA injection were pulled from borosilicate glass
(Drummond Scientific, Broomall, PA) on a Sutter P87 horizontal puller,
and the tips were cut with forceps to ⬇40 m in diameter. The cRNA,
with proper dilution in diethyl pyrocarbonate-treated water, was drawn
up into the micropipette and injected into oocytes with a Nanoject
microinjection system (Drummond Scientific) at a total volume of
20 – 60 nl.
Electrophysiology—One to three days after cRNA injection, the oocyte was placed in a 100-l chamber with continuous oocyte Ringer
perfusion. The oocyte Ringer was used as an extracellular solution,
which consisted of (in mM) 92.5 NaCl, 2.5 KCl, 1 CaCl2, 1 MgCl2, and 5
HEPES, pH 7.5. The chamber was grounded through an agarose bridge
to prevent the influence of the cysteine modification reagent on the
reference electrode. The oocytes were voltage-clamped at ⫺70 mV to
measure GABA-induced currents using a GeneClamp 500 (Axon Instruments, Foster City, CA). For the cysteine accessibility test, 1 mM MTSET was applied for 1 min. The current responses to GABA at a

concentration inducing ⬃20% of the maximum GABA response (⬃EC20)
were examined before and after MTSET modification. For agonist/
antagonist protection, a super-saturation concentration (⬎100-fold of
EC50) of agonist/antagonist was co-applied with 1 mM MTSET for 1 min
to ensure adequate protection in the binding pocket.
Drug Preparation—GABA (Calbiochem) stock solution (100 mM) was
prepared daily from the solid. 3-Aminopropylphosphonic acid (3-APA,
Sigma) stock solution (100 mM) was prepared and frozen in aliquots
before use. MTSET (Toronto Research Chemicals, Toronto, Canada)
stock solution (100 mM) was prepared in pure water and frozen in
aliquots. MTSET (1 mM in OR2) was freshly prepared from the stock
solution for each oocyte immediately before use.
Data Analysis—The dose-response relationship of the GABA-induced
current in recombinant GABAC receptors was least squares fit to the
following Hill equation
I⫽

Imax
1 ⫹ (EC50/[GABA])n

(Eq. 1)

where the GABA-induced current (I) is a function of the GABA concentration, EC50 is the GABA concentration required for inducing a halfmaximal current, n is the Hill coefficient, and Imax is the maximum
current. The maximum current was then used to normalize the doseresponse curve for each individual oocyte. The average of the normalized currents for each GABA concentration was used to plot the data.
All the data were presented as mean ⫾ S.E. (standard error).
Statistics—The statistical significance of the effect of MTSET on the
GABA-induced current in wild type and mutant receptors was evaluated by one-way analysis of variance with the Dunnett post test. The
significance of agonist/antagonist protection of MTSET modulation was
evaluated by grouped student t test using GraphPad Prism 4.0 (GraphPad Software, Inc., San Diego, CA).
Homology Modeling—Three-dimensional modeling of the 1 GABA
receptor amino-terminal domain was made based on the crystal structure of AChBP deposited in the Protein Data Bank (Protein Data Bank
code 1I9B (11)). Low sequence homology between GABA receptor and
AChBP did not allow straightforward or confident modeling by commonly used automatic methods such as Swiss-Model (21). Thus, a
manual method was used. An electron density map of AChBP was
calculated to 1.8 Å resolution, based on the coordinates of one of the
monomers in the 1I9B Protein Data Bank entry. The AChBP model was
imbedded in the electron density. With the sequence alignment as a
guide, residues of the AChBP model were graphically mutated using the
molecular graphics program QUANTA (Accelrys, San Diego, CA). Residues were mutated to residue types as indicated by sequence alignment along randomly chosen stretches of the AChBP sequence. The new
side chain atoms were automatically best fit into the electron density by
the QUANTA program. The best rotamers were chosen to fit density
and avoid steric clashes with other parts of the molecule. Where deletions and insertions were made, structural regularization and the best
rotamers were used to model surrounding and inserted residues. Manual movements of residues and side chains were made when the
QUANTA automatic features were not able to resolve steric clashes.
The parts of the sequence that were homologous provided many points
between which regularization could be anchored. After the entire sequence was mutated and manually modeled, the structure was energyminimized using the Crystallography and NMR System (CNS) program
suite (22). The structural alignment program TOP (23) was used to
align the modeled monomer with each of the five AChBP monomers in
the 1I9B structure. Finally, the entire pentameric structure, with sequences mutated to that of the GABA receptor, was energy-minimized
using CNS.
Visualization of the Binding Pocket—For three-dimensional presentation of the binding pocket, the newly identified binding residues along
with the previously identified ones were mapped onto the homology
model using the molecular graphics program Deep View. The resulting
image was saved as a POV-Ray 3.5 scene file. The final image of the
model was rendered by POV-Ray 3.6 software.
RESULTS

Location of the Scanning Regions—To determine the scanning regions, we used the AChBP-based structural model of the
amino-terminal domain of ligand-gated ion channels as a reference. Fig. 1 shows the alignment of the 1 GABA receptor
subunit and AChBP partial sequences. We defined six potential
binding loops in the GABA receptor 1 subunit (Fig. 1, underlined residues). Since the critical residues for agonist binding in

Downloaded from http://www.jbc.org/ at ELSEVIER BV on September 19, 2019

By testing the functional effect of a water-soluble cysteine
modification reagent and blockability of this effect by agonist
and antagonist, the substituted cysteine accessibility method
has also been successfully used to probe the binding sites of the
GABAA (6, 17) and nicotinic receptors (18, 19). With this approach, novel residues involved in agonist binding were identified, and the secondary structures of the newly identified
domain were predicted (6, 7).
In this study, using cysteine accessibility scanning and agonist/antagonist protection tests, we have identified amino acid
residues involved in agonist binding in novel regions of the 1
GABAC receptor subunit corresponding to loops A and E in
nicotinic receptor subunits. The newly identified binding residues in loop A and part of loop E are in comparable positions as
in the GABAA receptor. Moreover, in the extended stretch of
loop E, a region previously unexplored in GABA-gated ion
channels, we have identified three novel binding residues in
the 1 GABAC receptor. In contrast to the GABAA receptor, loop
F in the 1 homomeric GABAC receptor does not appear to be
involved in agonist binding. Using the AChBP crystal structure
as a template, we have built a homology model for the aminoterminal domain of the 1 GABA receptor. These newly discovered binding residues, along with previously identified binding
residues, are mapped to the homology model to construct a
complete agonist binding pocket for the GABAC receptor.

Novel GABAC Receptor Binding Sites
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FIG. 1. Location of the cysteine scanning regions. The partial amino acid sequence of the GABA receptor 1 subunit amino-terminal domain
was aligned to the sequence of the model molecule, AChBP, by ClustalW. The six loops (A–F) identified as participating in the formation of the
agonist binding pocket of nicotinic receptors are underlined, and the key amino acid residues identified as binding site residues in nicotinic
receptors and GABA receptors are in bold. The cysteine scanning residues of the 1 GABA receptor subunit in this study are marked with a c in
loops A, E, and F.
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FIG. 2. Functional properties of individual cysteine mutants of the 1
GABA receptor. A, dose-response curves
for the mutants with a significant change
in GABA sensitivity. The lines are least
squares fits of the data to Equation 1. B,
-fold change in EC50 (normalized to wild
type receptor) of each cysteine mutant in
the three putative binding loops. The EC50
values of functional mutants are listed in
Table I. NF, nonfunctional; LE, low expression; SO, spontaneously opening.

loops B, C, and D of the 1 GABA receptor subunit have been
previously identified (highlighted in bold) (2, 13), in this study,
we selected loops A, E, and F of the 1 GABA receptor subunit
for cysteine scanning. The bold letters in the AChBP highlight
the amino acid residues previously identified to participate in
the formation of the agonist binding pocket in nicotinic receptors. The residues of the 1 GABA receptor subunit marked
with a c above the residue are designated for cysteine scanning
in this study.
Functional Properties of the Cysteine Mutants—Wild type
and single cysteine mutants were individually expressed in

Xenopus oocytes. The functional expression and dose-response
relationship were examined for all the constructs. Fig. 2A
shows dose-response relationships of representative mutants
with significant changes in GABA sensitivities. Using least
squares fitting to individual GABA dose-response relationships
with Equation 1, we have derived EC50 values for the wild type
and mutant receptors (Table I). -Fold changes in the EC50 for
all mutants (normalized to the wild type receptor) are plotted
in Fig. 2B. The alternating pattern in EC50 changes between
L166C and V171C in loop E and between S223C and F227C in
loop F may suggest a ␤-strand structure in these two regions.
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TABLE I
EC50 values determined from the GABA dose-response relationship in the individual cysteine mutants of the 1 homomeric GABA receptor
NF, nonfunctional; LE, low expression; SO, spontaneously opening.
Loop A
Mutant

Loop E
Mutant

NF
0.66 ⫾ 0.02
NF
387.6 ⫾ 62.3
0.72 ⫾ 0.07
5.94 ⫾ 0.43
NF
0.39 ⫾ 0.07
3.65 ⫾ 0.41
2.41 ⫾ 0.17
LE
1.66 ⫾ 0.06
8.50 ⫾ 0.51
SO
3.92 ⫾ 0.38

V155C
M156C
L157C
R158C
V159C
Q160C
P161C
D162C
G163C
K164C
V165C
L166C
Y167C
S168C
L169C
R170C
V171C

M

W133C
V134C
P135C
D136C
M137C
F138C
F139C
V140C
H141C
S142C
K143C
R144C
S145C
F146C
I147C

M

Note that in loop A, mutants W133C, P135C, and F139C are
not functional. Interestingly, the F146C mutant exhibited a
high leak current in the absence of GABA, which was blocked
by picrotoxin (data not shown). This suggests that the mutation
created a spontaneously opening channel. This residue is
aligned to an interface residue, Lys-94, in AChBP. In loop E,
G163C was nonfunctional. This residue is conserved across the
subunits in the ligand-gated ion channel family and is located
in the subunit interface in AChBP. In the same loop, the
expression of the mutant R158C was extremely low, and the
mutants L166C and S168C showed a significant increase in
EC50, suggesting that they may be involved in ligand binding.
In fact, these three residues are aligned to the ligand binding
residues Arg-104, Leu-112, and Met-114 in the AChBP (11)
(Fig. 1). The mutant Q160C also showed spontaneous opening
in the absence of agonist. This residue is presumably aligned to
another ligand binding residue, Val-106, in AChBP. In loop F,
only minor changes in channel function were observed (Table
I), with the most significant change being an ⬃20-fold increase
in the EC50 (Q226C).
Accessibility of the Engineered Cysteine by MTSET—To further delineate the binding pocket of the 1 GABAC receptor, we
examined the accessibility of the individual engineered cysteines in putative loops A, E, and F to a water-soluble thioreactive compound, MTSET. The oocytes were treated with 1
mM MTSET for 1 min. The currents induced by a GABA concentration (⬃EC20) before and after the MTSET treatment
were recorded for each cell. The normalized current change
upon treatment was calculated and plotted in Fig. 3. MTSET
treatment of the wild type receptor did not significantly alter
the GABA-induced current. Therefore, any significant change
after MTSET treatment is due to the modification of the engineered cysteine by this compound.
For loop A, MTSET had a significant effect on the GABAinduced currents in the oocytes expressing D136C, F138C,
V140C, H141C, and I147C, suggesting that residues at these
positions are accessible to MTSET modification. Accessible mutants in loop E were V155C, M156C, V159C, L166C, S168C,
and R170C. In loop F, most of the residues (L216C, T218C,
D219C, R221C, I222C, L224C, S225C, Q226C, and F227C)
were accessible. After reacting with MTSET, S225C in loop F
opened in the absence of GABA.
Protection of Accessible Residues by GABA—If a cysteine
residue lines the agonist binding pocket, then the binding of
agonist to the receptor would block or restrict the accessibility

Loop F
EC50

Mutant

0.88 ⫾ 0.06
7.21 ⫾ 0.94
1.53 ⫾ 0.20
LE
0.97 ⫾ 0.05
SO
0.85 ⫾ 0.05
0.71 ⫾ 0.02
NF
0.69 ⫾ 0.10
2.17 ⫾ 0.12
13.04 ⫾ 1.56
0.52 ⫾ 0.05
399.9 ⫾ 70.7
0.17⫾.00
10.84 ⫾ 2.23
0.65 ⫾ 0.06

L216C
K217C
T218C
D219C
E220C
R221C
I222C
S223C
L224C
S225C
Q226C
F227C

EC50

M

0.60 ⫾ 0.03
0.75 ⫾ 0.06
1.03 ⫾ 0.04
3.02 ⫾ 0.25
1.46 ⫾ 0.11
0.51 ⫾ 0.02
0.50 ⫾ 0.03
0.66 ⫾ 0.01
3.38 ⫾ 0.36
0.53 ⫾ 0.02
17.6 ⫾ 3.58
0.38 ⫾ 0.32

FIG. 3. The accessibility to MTSET of the cysteine mutants in
loops A, E, and F. The wild type and individual cysteine mutants were
examined for accessibility of a water soluble thio-reactive compound,
MTSET (1 mM for 1 min) using a GABA concentration ⬃EC20 for each
mutant as a test pulse. Examples of current traces of mutants D136C
(loop A), M156C (loop E), and L224C (loop F) before and after MTSET
treatment are shown above each plot. The normalized changes of the
GABA-induced current after MTSET treatment ((Iafter ⫺ Ibefore)/Ibefore)
are presented as bar graphs. A filled bar represents an MTSET effect on
the mutant that was statistically different from the wild type control.
NF, nonfunctional mutant; LE, low expression; SO, spontaneously
opening; SOM, spontaneously opening after modification.

of that residue to a modification reagent. To examine whether
the accessible cysteines can be blocked by GABA, a saturating
concentration of GABA was co-applied with 1 mM MTSET. The
co-application of GABA with MTSET significantly reduced the
alteration of the GABA response by MTSET for the following
mutants: D136C, F138C, and V140C in loop A and V155C,
M156C, V159C, S168C, and R170C in loop E (Fig. 4). Surprisingly, none of the residues in loop F were protected by GABA
from MTSET modification. These results suggest that loop F of
GABAC 1 receptor may not line the GABA binding pocket,
whereas the GABA-protected residues in loops A and E are
potential residues participating in the formation of the GABA
binding pocket. However, due to global conformational changes
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induced by GABA, accessibility of residues in other regions of
the receptor distant from the agonist binding pocket would
potentially be altered in the presence of GABA. Therefore, a
competitive antagonist protection experiment would further
test whether these residues line the binding pocket.
Protection of Accessible Residues by 3-APA—3-APA is a
GABAC receptor-competitive antagonist, presumably competing with the agonist for the same binding site but without
inducing a similar conformational change (24). A saturating
concentration of 3-APA was co-applied with 1 mM MTSET to
the oocytes expressing individual cysteine mutants of the 1
GABA receptor. Fig. 5 shows that 3-APA has a protection
pattern similar to that for GABA. That is, the mutants D136C,
F138C, and V140C in loop A and the mutants V155C, M156C,
V159C, S168C, and R170C in loop E were efficiently protected
by this competitive antagonist, whereas no residue in loop F
was protected. These data suggest that D136C, F138C, and
S142C in loop A and V155C, M156C, V159C, S168C, and
R170C in loop E are most likely lining the agonist/antagonist
binding pocket of the GABA 1 receptor.
DISCUSSION

Identification of Novel Binding Residues in the Binding Pocket—If a residue directly interacts with the agonist, then mutation of the residue would be expected to decrease the binding
affinity. With the cysteine mutations, we have identified several residues that, when mutated, reduced agonist sensitivity
of the GABA receptor. The sensitivity decrease by mutation
could be due to the reduction of binding affinity or a decrease in
the maximum open probability (25). A pure gating effect on
EC50, however, is limited in the 1 homomeric GABA receptor.
For example, the previously established three-bind-to-open
model (26) predicts that a decrease in gating efficiency of 100fold in the 1 homomeric GABA receptor would only result in an

FIG. 5. Protection pattern of the accessible residues in the
three loops by competitive antagonist, 3-APA. Each functionally
accessible cysteine mutant was tested by an ⬃EC20 GABA concentration. One mM MTSET was used for modification. A saturating concentration of 3-APA was co-applied with MTSET to test for protection. An
asterisk indicates a statistically significant difference between groups
in the presence and absence of 3-APA for each mutant. The dashed lines
indicate the control level.

increase in the EC50 of ⬃4-fold (27). Thus, the mutations with
an increase in EC50 for more than 4-fold, such as D136C (loop
A), L166C, S168C, R170C (loop E), and Q226C (loop F), likely
have a decreased binding affinity in addition to any changes in
gating efficacy. The binding affinity decrease could be a direct
effect of the mutation in the binding site, or the mutation could
also allosterically influence binding by changing the conformation of the binding site from a distant location. These two
possibilities can be further differentiated by a combination of
cysteine accessibility and protection tests.
The mutants W133C, P135C, F139C (loop A), and G163C
(loop E) were not functional. These mutations probably influence receptor trafficking or assembly, although we cannot rule
out the possibility that the mutations directly disrupt the agonist binding site. For those mutants with minor changes in the
GABA sensitivity, the role of these residues in agonist binding
is probably less significant, although they might still line the
binding pocket.
To further determine whether a residue lines the binding
pocket, we tested the accessibility and agonist/antagonist protection of the engineered cysteines. A residue that lines the
binding pocket would become less accessible when the agonist
is bound. However, due to the ability of agonist to induce a
global conformational change related to channel opening, it is
possible that the agonist could change the conformation outside
the binding pocket and make that site less accessible to the
cysteine modification reagent. As a further test, we examined
protection by a competitive antagonist. Although recent studies
suggest that a competitive antagonist can also induce a conformational change beyond the binding site to stabilize the GABA
receptor in the closed state (17, 28, 29), this antagonist-induced
conformational change is distinct from that induced by the
agonist (24). Thus, only when the agonist and antagonist both
protect a residue from modification do we consider that residue
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FIG. 4. GABA protection pattern of the accessible residues in
the three loops. For all accessible residues identified, a GABA concentration ⬃EC20 was used for the test. One mM MTSET was used for
modification. About 100 ⫻ EC50 GABA concentration was co-applied
with MTSET to test protection. Note that the S225C mutant in loop F
showed spontaneously opening after MTSET modification and therefore
is not shown in the figure. This MTSET modification-induced opening
was not protected by GABA. An asterisk indicates a statistically significant difference between groups in the presence and absence of GABA.
The dashed lines indicate the control level.
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in the binding pocket. In this way, we have identified three
novel binding residues in loop A (Asp-136, Phe-138, and Val140) and five novel binding residues in loop E (Val-155, Met156, Val-159, Ser-168, and Arg-170). By these criteria, no binding residues were identified in loop F, suggesting that this loop
in the 1 GABA receptor is not directly involved in agonist
binding. Note that V140C, V155C, and V159C showed no significant change in GABA EC50, suggesting that they may not
directly contact the agonist but may still line the binding
pocket. In contrast, the L166C and Q226C mutants were 15–
20-fold less sensitive to GABA, suggesting a reduced binding
affinity. The two engineered cysteine residues, however, were
not protected by agonist or antagonist, indicating that they are
likely outside the binding pocket. The reduction of binding
affinity by these mutations could be due to an indirect/distant
effect on the binding pocket.
Since our goal was to detect dramatic changes in accessibility
caused by direct physical occlusion of binding residue by agonist/antagonist, we examined MTSET modification at a single
time. At least in terms of detecting minor changes in accessibility, this approach is less sensitive than an examination of
the reaction rate. Since L166C aligns with a binding site residue in the nicotinic receptor (11), we wanted to exclude the
possibility that we were missing this potential binding site
residue. We therefore examined the reaction rate of L166C to
MTSET in the absence and presence of 3-APA. Fig. 6 shows
that at a saturation concentration, 3-APA did not significantly
change the reaction rate at L166C, further confirming our
conclusion. Thus, although we cannot completely rule out the
possibility that some minor binding residues might be under
our detection threshold, the result gives us confidence that we
did not miss crucial binding site residues.
Spontaneously Opening Channels—In this study, we found
that mutations of F146C in loop A and Q160C in loop E created
spontaneously opening channels. Although the S225C mutation in loop F did not create a spontaneously opening channel,
modification of this engineered cysteine by MTSET made the
channel open spontaneously. The mutation of Y102S in loop D
(13) and several mutations in the channel lining domain (29 –
32) also created spontaneously opening channels. The fact that
spontaneously opening channels can be created by mutations
in different loops of the amino-terminal domain or in the porelining domain suggests that channel gating is not exclusively
controlled by a single residue. Instead, the energy landscape

maintaining a proper conformation of the agonist binding site
and gating machinery is governed by an interconnected allosteric network. Perturbation of this allosteric network, either by
agonist binding or by mutation at one of the key positions,
could alter the energy landscape to stabilize the receptor in the
open state. In the amino-terminal domain of the 1 GABA
receptor, these key positions, including residues Tyr-102 (loop
D), Phe-146 (in loop A), Gln-160 (in loop E), and Ser-255 (in loop
F), are distributed in multiple binding (or coupling) loops. The
coordinated movement of these loops induced by agonist could
be an important mechanism for channel activation. It is interesting that a mutation at a different position (L99C) in loop A
of the ␤2 subunit also created a spontaneously opening channel
(7). In contrast, the mutant V140C in the homologous position
of the 1 subunit was not spontaneously active. This difference
in key sites of the gating determinants may contribute to the
distinct gating kinetics of GABAA and GABAC receptors.
Secondary Structure Prediction—As indicated in Fig. 2, the
alternating change in EC50 upon cysteine mutation in the
segments L166C–V171C of loop E and S223C–F227C of loop F
suggests a ␤-strand structure. The ␤-strand structure of segment L166C–V171C of loop E is further supported by the
alternating accessibility pattern in this region (Fig. 3). In loop
F, however, the pattern of accessibility to MTSET suggests a
random coil. In addition, an alternating pattern of accessibility
to MTSET in the segment Asp-136 –Val-140 in loop A also
suggests a ␤-strand structure. The secondary structure predictions in these loops of the 1 GABA receptor are in agreement
with the crystal structure of the homologous protein, AChBP,
and similar to the predictions in the homologous regions of the
␣1 (8, 9) and ␤2 (7) subunits of the GABAA receptor.
Comparison with the Residues Lining the GABAA Receptor
Agonist Binding Pocket—GABAA and GABAC receptors share
many agonists, such as GABA and muscimol, but have distinct competitive antagonists, such as bicuculline for GABAA
and 1,2,5,6-tetrahydropyridine-4-yl)methylphosphinic acid for
GABAC. Agonist sharing suggests that they have similar overall architecture in the agonist/antagonist binding pocket,
whereas the distinct antagonist profile suggests that their agonist/antagonist binding pockets are not identical. Thus, when
we use agonist and competitive antagonist protection of the
modification of the engineered residues as criteria for binding
site residues, it would result in identification of some common
and distinct residues lining the binding pocket. Fig. 7 shows all
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FIG. 6. 3-APA, at a saturation concentration, did not change the reaction rate of MTSET at L166C. A, current traces induced by 3 M GABA and
modification by MTSET (100 M) in the
presence or absence of 3-APA (1 mM). B,
normalized and averaged data of MTSET
modification with single exponential fits
(lines). Note that in the presence of 1 mM
3-APA, the rate of the current decay induced by MTSET modification did not
change. C, the average MTSET reaction
rate determined by fitting data from individual oocytes with a single exponential
function. The rates were second-order
rates (normalized to the MTSET concentration). Note that there was no significant difference in the rates in the presence or absence of 3-APA. D, dosedependent inhibition of the 15 M GABAinduced current by 3-APA, showing
saturation of 3-APA inhibition at 1 mM.
The continuous line is the least squares fit
of the data to a Hill equation. The error
bars are smaller than the symbol.
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FIG. 7. Comparison of the binding residues in GABAC and GABAA receptors. The partial amino acid sequence of the human GABA
receptor 1 subunit amino-terminal domain is aligned to the homologous region of the rat ␣1 and ␤2 subunits. The six putative binding loops (A–F)
are underlined. The key amino acid residues identified as binding site residues in GABAC and GABAA receptors are in bold.

the binding residues identified to date in the 1 (GABAC) and
␣1/␤2 (GABAA) subunits. In loops B, C (2), and D (5, 13), the
binding residues identified by site-directed mutagenesis are
almost identical. In loop D, two additional binding residues,
Arg-66 and Ser-68, in the ␣1 subunit are recognized by the
substituted cysteine accessibility method (6, 17). The corresponding residue Arg-104 in the 1 subunit seems to line the
binding pocket.2 Our newly identified binding residues in loop
A of the 1 subunit, Phe-138 and Val-140, can find their homologous counterparts (Tyr-97 and Leu-99) in the ␤2 subunit (7).
However, the binding residue Aps-136 in the same loop of the
1 subunit is distinct from that in the ␤2 subunit. This suggests
that the 1 subunit in this region adopts a slightly different
conformation than the corresponding region of the ␤2 subunit.
In loop E, our results indicate that Ser-168 and Arg-170 line
the binding pocket of the 1 GABA receptor, similar to the
homologous residues (Thr-129 and Arg-131) in the ␣1 subunit
(9). In addition, we have identified three more binding residues
(V155C, M156C, and V159C) in the extended region of loop E,
but it belongs to a different ␤-strand, of the 1 subunit. This
2

V. Torres and D. S. Weiss, personal communication.

region in the ␣1 subunit has not yet been explored. In loop F, we
could not find any residue meeting our criteria for a binding
site lining residues in the 1 GABA receptor. In contrast, three
residues (Val-178, Val-180, and Asp-183) in loop F of the ␣1
subunit have been identified as binding site residues (8). This
major difference between GABAC and GABAA could, in part,
underlie the functional and pharmacological diversities between these two types of GABA receptors.
Model for the 1 GABAC Receptor Binding Pocket—Using
cysteine scanning accessibility, we have successfully identified
novel residues in the 1 GABA receptor involved in GABA
binding. With these data and previously identified binding
residues in other loops, we were able to construct a model for
the 1 GABA receptor binding pocket. For a three-dimensional
presentation of the agonist/antagonist binding pocket, we first
built a structural model for the amino-terminal domain of the
1 GABA receptor by homology modeling using AChBP as a
template. The binding residues experimentally identified to
date, as highlighted in Fig. 7, were then mapped onto this
structural model and highlighted with the side chain (Fig. 8).
The residues from loops A (red), B (cyan), and C (green) form
one face of the binding pocket. The complementary face of the
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FIG. 8. Model for the 1 GABAC receptor agonist/antagonist binding
pocket. The binding residues identified
in all five loops were mapped onto the
homology model of the amino-terminal
domain of the 1 GABA receptor. These
residues form a putative agonist/antagonist binding pocket in the subunit interface. (One of the five potential binding
pockets in a receptor is shown.) Residues
Asp-136, Phe-138, and Val-140 in loop A
(red), Tyr-198 and Tyr-200 in loop B
(cyan), and Tyr-241, Thr-244, and Tyr247 in loop C (green) form the principal
face of the binding pocket, whereas residues Tyr-102 and Arg-104 in loop D (yellow) and Val-155, Met-156, Val-159, Ser168, and Arg-170 in loop E (purple) form
the complimentary face of the binding
pocket.
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binding pocket is formed by residues from loops D (yellow) and
E (purple). Loop F is in the vicinity of the binding pocket but
does not directly contribute to agonist binding. Note that all
these presumed binding residues are pointing toward the putative GABA binding pocket with the exception of Val-155 and
Val-159. Mutation of these residues to cysteine did not significantly alter the GABA EC50 of the receptor. Thus, it is possible
that these residues are not in the binding pocket in the absence
of agonist/antagonist, but a local conformational change induced by binding of the agonist or antagonist can alter their
orientation and thus change their accessibility. Although the
precise location of each residue still awaits the high resolution
structure of the GABAC receptor, the excellent agreement of
most experimentally identified binding residues and the homology model further strengthens our conclusion that the identified residues are actually lining the agonist binding pocket of
the receptor.
REFERENCES

Downloaded from http://www.jbc.org/ at ELSEVIER BV on September 19, 2019

1. Johnston, G. (1996) Trends Pharmacol. Sci. 17, 319 –323
2. Amin, J., and Weiss, D. (1994) Receptors Channels 2, 227–236
3. Chang, Y., Gansah, E., Chen, Y., Ye, J., and Weiss, D. (2002) J. Neurosci. 22,
7982–7990
4. Amin, J., and Weiss, D. (1993) Nature 366, 565–569
5. Sigel, E., Baur, R., Kellenberger, S., and Malherbe, P. (1992) EMBO J. 11,
2017–2023
6. Boileau, A., Evers, A., Davis, A., and Czajkowski, C. (1999) J. Neurosci. 19,
4847– 4854
7. Boileau, A., Glen Newell, J., and Czajkowski, C. (2002) J. Biol. Chem. 277,
2931–2937

8. Newell, J., and Czajkowski, C. (2003) J. Biol. Chem. 278, 13166 –13172
9. Holden, J., and Czajkowski, C. (2003) Society for Neuroscience 33rd Annual
Meeting, New Orleans, Nov. 8 –12, 2003, Program Number 50.10, Society for
Neuroscience, Washington, D. C.
10. Corringer, P., Le Novère, N., and Changeux, J. (2000) Annu. Rev. Pharmacol.
Toxicol. 40, 431– 458
11. Brejc, K., van Dijk, W. J., Klaassen, R. V., Schuurmans, M., van Der Oost, J.,
Smit, A. B., and Sixma, T. K. (2001) Nature 411, 269 –276
12. Smith, G., and Olsen, R. (1994) J. Biol. Chem. 269, 20380 –20387
13. Torres, V., and Weiss, D. (2002) J. Biol. Chem. 277, 43741– 43748
14. Akabas, M., Stauffer, D., Xu, M., and Karlin, A. (1992) Science 258, 307–310
15. Xu, M., and Akabas, M. (1996) J. Gen. Physiol. 107, 195–205
16. Wilson, G., and Karlin, A. (1998) Neuron 20, 1269 –1281
17. Holden, J., and Czajkowski, C. (2002) J. Biol. Chem. 277, 18785–18792
18. Sullivan, D., Chiara, D., and Cohen, J. (2002) Mol. Pharmacol. 61, 463– 472
19. Sullivan, D., and Cohen, J. (2000) J. Biol. Chem. 275, 12651–12660
20. Chang, Y., and Weiss, D. (1999) Nature Neuroscience 2, 219 –225
21. Schwede, T., Kopp, J., Guex, N., and Peitsch, M. (2003) Nucleic Acids Res. 31,
3381–3385
22. Brunger, A., Adams, P., Clore, G., DeLano, W., Gros, P., Grosse-Kunstleve, R.,
Jiang, J., Kuszewski, J., Nilges, N., Pannu, N., Read, R., Rice, L., Simonson,
T., and Warren, G. (1998) Acta Crystallogr. Sect. D Biol. Crystallogr. 54,
905–921
23. Lu, G. (2000) J. Appl. Crystallogr. 33, 176 –183
24. Chang, Y., and Weiss, D. (2002) Nature Neuroscience 5, 1163–1168
25. Colquhoun, D. (1998) Br. J. Pharmacol. 125, 923–948
26. Amin, J., and Weiss, D. (1996) Proc. R. Soc. Lond. B Biol. Sci. 263, 273–282
27. Chang, Y., Covey, D., and Weiss, D. (2000) Mol. Pharmacol. 58, 1375–1380
28. Ueno, S., Bracamontes, J., Zorumski, C., Weiss, D., and Steinbach, J. (1997)
J. Neurosci. 17, 625– 634
29. Chang, Y., and Weiss, D. (1999) Biophys. J. 77, 2542–2551
30. Chang, Y., and Weiss, D. (1998) Mol. Pharmacol. 53, 511–523
31. Pan, Z., Zhang, D., Zhang, X., and Lipton, S. (1997) Proc. Natl. Acad. Sci.
U. S. A. 94, 6490 – 6495
32. Chang, Y., Wang, R., Barot, S., and Weiss, D. (1996) J. Neurosci. 16,
5415–5424

Mapping the ρ1 GABAC Receptor Agonist Binding Pocket: CONSTRUCTING A
COMPLETE MODEL
Anna Sedelnikova, Craig D. Smith, Stanislav O. Zakharkin, Delores Davis, David S.
Weiss and Yongchang Chang
J. Biol. Chem. 2005, 280:1535-1542.
doi: 10.1074/jbc.M409908200 originally published online November 17, 2004

Access the most updated version of this article at doi: 10.1074/jbc.M409908200

Click here to choose from all of JBC's e-mail alerts
This article cites 31 references, 15 of which can be accessed free at
http://www.jbc.org/content/280/2/1535.full.html#ref-list-1

Downloaded from http://www.jbc.org/ at ELSEVIER BV on September 19, 2019

Alerts:
• When this article is cited
• When a correction for this article is posted

